Literature DB >> 21291860

Integrin αβ1, αvβ, α6β effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance.

Hope A Sansing1, Ali Sarkeshik, John R Yates, Vyomesh Patel, J Silvio Gutkind, Kenneth M Yamada, Allison L Berrier.   

Abstract

Ligand engagement by integrins induces receptor clustering and formation of complexes at the integrin cytoplasmic face that controls cell signaling and cytoskeletal dynamics critical for adhesion-dependent processes. This study searches for a subset of integrin effectors that coordinates both tumor cell invasion and resistance to the chemotherapeutic drug cisplatin in oral carcinomas. Candidate integrin effectors were identified in a proteomics screen of proteins recruited to clustered integrin αβ1, α(v)β or α(6)β receptors in oral carcinomas. Proteins with diverse functions including microtubule and actin binding proteins, and factors involved in trafficking, transcription and translation were identified in oral carcinoma integrin complexes. Knockdown of effectors in the oral carcinoma HN12 cells revealed that p130Cas, Dek, Src and talin were required for invasion through Matrigel. Disruption of talin or p130Cas by RNA interference increased resistance to cisplatin, whereas targeting Dek, Src or zyxin reduced HN12 resistance to cisplatin. Analysis of the spreading of HN12 cells on collagen I and laminin I revealed that a decrease in p130Cas or talin expression inhibited spreading on both matrices. Interestingly, a reduction in zyxin expression enhanced spreading on laminin I and inhibited spreading on collagen I. Reduction of Dek, Src, talin or zyxin expression reduced HN12 proliferation by 30%. Proliferation was not affected by a reduction in p130Cas expression. We conclude that p130Cas, Src and talin function in both oral carcinoma invasion and resistance to cisplatin.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21291860      PMCID: PMC3102534          DOI: 10.1016/j.bbrc.2011.01.109

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

1.  Cell-spreading assays.

Authors:  Allison L Berrier; Susan E LaFlamme
Journal:  Methods Mol Biol       Date:  2005

Review 2.  From the membrane to the nucleus and back again: bifunctional focal adhesion proteins.

Authors:  Martial Hervy; Laura Hoffman; Mary C Beckerle
Journal:  Curr Opin Cell Biol       Date:  2006-09-05       Impact factor: 8.382

Review 3.  Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?

Authors:  Pol M Specenier; Jan B Vermorken
Journal:  Cancer Lett       Date:  2007-07-27       Impact factor: 8.679

Review 4.  Invasion assays.

Authors:  H K Kleinman; K Jacob
Journal:  Curr Protoc Cell Biol       Date:  2001-05

5.  Preparation of extracellular matrices produced by cultured corneal endothelial and PF-HR9 endodermal cells.

Authors:  I Vlodavsky
Journal:  Curr Protoc Cell Biol       Date:  2001-05

6.  Uncoupling of epidermal growth factor-dependent proliferation and invasion in a model of squamous carcinoma progression.

Authors:  W Andrew Yeudall; Hiroshi Miyazaki; John F Ensley; Massimo Cardinali; J Silvio Gutkind; Vyomesh Patel
Journal:  Oral Oncol       Date:  2005-08       Impact factor: 5.337

Review 7.  Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance.

Authors:  Mary M Zutter
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

8.  Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin.

Authors:  Yoshio Yoshida; Tetsuji Kurokawa; Yukiko Nishikawa; Makoto Orisa; Hynda K Kleinman; Fumikazu Kotsuji
Journal:  Int J Oncol       Date:  2008-03       Impact factor: 5.650

9.  Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells.

Authors:  Ilya Serebriiskii; Remedios Castelló-Cros; Acacia Lamb; Erica A Golemis; Edna Cukierman
Journal:  Matrix Biol       Date:  2008-03-06       Impact factor: 11.583

10.  Non-invasive imaging of barriers to drug delivery in tumors.

Authors:  Yaron Hassid; Erez Eyal; Raanan Margalit; Edna Furman-Haran; Hadassa Degani
Journal:  Microvasc Res       Date:  2008-06-27       Impact factor: 3.514

View more
  17 in total

1.  miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.

Authors:  Khalid Sossey-Alaoui; Edward F Plow
Journal:  Mol Cancer Res       Date:  2015-10-16       Impact factor: 5.852

2.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

3.  A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement.

Authors:  Rosa Bosch; María José Moreno; Rebeca Dieguez-Gonzalez; María Virtudes Céspedes; Alberto Gallardo; Manuel Trias; Albert Grañena; Jorge Sierra; Isolda Casanova; Ramon Mangues
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 4.  Concise review: role of DEK in stem/progenitor cell biology.

Authors:  Hal E Broxmeyer; Nirit Mor-Vaknin; Ferdinand Kappes; Maureen Legendre; Anjan K Saha; Xuan Ou; Heather O'Leary; Maegan Capitano; Scott Cooper; David M Markovitz
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

Review 5.  The mesenchymal tumor microenvironment: a drug-resistant niche.

Authors:  Edna Cukierman; Daniel E Bassi
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

6.  Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.

Authors:  Xiao-Feng Le; Maria I Almeida; Weiqun Mao; Riccardo Spizzo; Simona Rossi; Milena S Nicoloso; Shu Zhang; Yun Wu; George A Calin; Robert C Bast
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

Review 7.  Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.

Authors:  Nicholas A Saunders; Fiona Simpson; Erik W Thompson; Michelle M Hill; Liliana Endo-Munoz; Graham Leggatt; Rodney F Minchin; Alexander Guminski
Journal:  EMBO Mol Med       Date:  2012-06-25       Impact factor: 12.137

Review 8.  ErbB/integrin signaling interactions in regulation of myocardial cell-cell and cell-matrix interactions.

Authors:  Laura Pentassuglia; Douglas B Sawyer
Journal:  Biochim Biophys Acta       Date:  2012-12-20

9.  Quantum dots for cancer research: current status, remaining issues, and future perspectives.

Authors:  Min Fang; Chun-Wei Peng; Dai-Wen Pang; Yan Li
Journal:  Cancer Biol Med       Date:  2012-09       Impact factor: 4.248

10.  Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.

Authors:  Verena Paulitschke; Verena Haudek-Prinz; Johannes Griss; Walter Berger; Thomas Mohr; Hubert Pehamberger; Rainer Kunstfeld; Christopher Gerner
Journal:  J Proteome Res       Date:  2013-06-19       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.